• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Anette Breindl

Articles by Anette Breindl

For lower drug prices, something better than outrage

June 25, 2019
By Anette Breindl
Cutting pills in half is currently an act of desperation by those who can't afford the full amount their doctor has prescribed. But for some of the most expensive drugs on the market – cancer drugs – there are a number of drugs where cutting the dose by half, or by more, can result in treatment that is just as effective, and cuts financial toxicity and, possibly, other toxicity risks as well.
Read More

Beyond POLO, string of ponies running on large DDR field

June 24, 2019
By Anette Breindl
One of the highlights of the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) earlier this month were results from the phase III POLO trial, demonstrating that treatment with Lynparza (olaparib, Astrazeneca plc/Merck & Co. Inc.) after platinum chemotherapy nearly doubled the progression-free interval (progression-free survival, PFS) in a group of 154 metastatic pancreatic cancer patients with germline BRCA mutations, from 3.8 months to 7.4 months.
Read More

Beyond POLO, string of ponies running on large DDR field

June 24, 2019
By Anette Breindl
One of the highlights of the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) earlier this month were results from the phase III POLO trial, demonstrating that treatment with Lynparza (olaparib, Astrazeneca plc/Merck & Co. Inc.) after platinum chemotherapy nearly doubled the progression-free interval (progression-free survival, PFS) in a group of 154 metastatic pancreatic cancer patients with germline BRCA mutations, from 3.8 months to 7.4 months.
Read More

Bench Press: BioWorld looks at translational medicine

June 24, 2019
By Anette Breindl
Two separate research groups, one at the Barcelona Institute of Science and Technology and one at Harvard Medical School, have discovered a way to predict 3D protein structures by focusing on mutated versions of the proteins that affected epistatic interactions. 
Read More

Half-used medicine cabinet means half-full glass for CLL

June 18, 2019
By Anette Breindl
AMSTERDAM – Since 2014, approvals and expanding indications for Bruton's tyrosine kinase (BTK) inhibitors Imbruvica (ibrutinib, Pharmacyclics LLC/Janssen Biotech Inc.) and Calquence (acalabrutinib, Astrazeneca plc), and Bcl-2 inhibitor Venclexta (venetoclax, Abbvie Inc./Roche AG) have given many chronic lymphocytic leukemia (CLL) patients chemotherapy-free treatment options. Many cancer patients dread chemotherapy almost as much as they dread their cancer, and frail patients may be unable to withstand the toxicities of chemotherapy and greatly prefer those chemotherapy-free regimens.
Read More

Gut microbe enzymes can convert blood from type A to type O

June 17, 2019
By Anette Breindl

Multiple approaches improve outlook for hemoglobinopathies

June 17, 2019
By Anette Breindl
AMSTERDAM – Sickle cell disease is "the most frequent red blood cell disorder worldwide," Jo Howard, of King's College London, told the audience at the 24th Congress of the European Hematology Association (EHA) on Friday. And with global migration patterns of the past decades, the disorder has gone from a tropical disease to global problem.
Read More

MCBS aims to separate wheat from chaff, expands to hematological cancers

June 17, 2019
By Anette Breindl
AMSTERDAM – "We are seeing a rapid explosion of new agents in malignancies," Nathan Cherny told the audience at the 23rd Congress of the European Hematology Association (EHA).
Read More

Bench Press: BioWorld looks at translational medicine

June 17, 2019
By Anette Breindl
Researchers at Columbia University have discovered that Vibrio cholerae has co-opted CRISPR Cas9 systems into transposons for horizontal gene transfer, and that those transposons were capable of site-specific gene editing without the need for double-stranded DNA breaks.
Read More

Gut microbe enzymes can convert blood from type A to type O

June 12, 2019
By Anette Breindl
Scientists have discovered a pair of gut microbial enzymes that worked in tandem to convert blood cells of the type A to those of type O by removing the surface molecule alpha-1,3-linked-N-acetylgalactosamine (GalNAc) from the surface of red blood cells.
Read More
Previous 1 2 … 101 102 103 104 105 106 107 108 109 … 392 393 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe